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 Abstract
Hymenoptera venom allergy is an epidemiologically underestimated condition and a major cause of morbidity worldwide. Preventing future 
allergic reactions in patients who experience a systemic reaction is based on the correct management of the emergency followed by an 
accurate diagnosis, prescription of adrenaline autoinjectors, and, where indicated, specific venom immunotherapy. Some epidemiological 
studies highlight our poor knowledge of this disease and the frequent inadequacy of its management. Moreover, they emphasize the 
importance of such a life-saving treatment as specific immunotherapy. The availability of high-quality hymenoptera venom extracts for 
diagnostic and therapeutic use has dramatically improved the prognosis and quality of life of allergic patients. Subcutaneous venom 
immunotherapy is currently the most effective form of allergen-based immunotherapy, with a carry-over effect lasting up to several years 
after its interruption. This report on the management of hymenoptera venom–allergic children and adults was prepared by a panel of Italian 
experts. The main objective of this consensus document is to review the scientific evidence related to diagnosis, therapy, and management 
of patients allergic to hymenoptera venom. Thus, we can improve our knowledge of the disease and promote good clinical practices. 
The present document provides practical suggestions for correct diagnosis, prescription of emergency therapy and immunotherapy, and 
strategies for patient care.
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Introduction
Hymenoptera venom allergy is an epidemiologically 
underestimated condition and a major cause of morbidity 
worldwide. Mortality is low, although underestimates are 
common, with many sting fatalities being misdiagnosed. 
Preventing future allergic reactions in patients who have 
developed a systemic reaction is based on correct management 
of the emergency followed by diagnosis, prescription of 
adrenaline autoinjectors, and, where indicated, specific venom 
immunotherapy (VIT). Some epidemiological studies highlight 
our poor knowledge of this disease and the frequent inadequacy 
of its management [1] and emphasize the importance of such 
an important life-saving treatment as specific immunotherapy.
The availability of high-quality hymenoptera venom 
extracts for diagnosis and therapy has dramatically improved 
the prognosis and quality of life of allergic patients. 
Subcutaneous VIT is currently the most effective form of 
allergen-based immunotherapy, with a carry-over effect lasting 
up to several years after its interruption. 
This report on the management of hymenoptera venom 
allergy was prepared by a panel of Italian experts. 
Objectives and Work Methodology 
The main objective of this consensus is to review 
scientific evidence associated with the diagnosis, treatment, 
and management of patients who are allergic to hymenoptera 
venom and thus to improve our knowledge of this disease 
and promote good clinical practice. This document provides 
practical suggestions for correct diagnosis, prescription of 
emergency therapy and immunotherapy, and strategies for 
the care of patients.
The data on the various topics addressed in this report were 
obtained from studies published in English and Italian and 
collected by searching the MEDLINE and EMBASE databases. 
The GRADE system was used for translating research results 
into recommendations based on scientific evidence (Table 1) [2]. 
We included all recommendations for which agreement was by 
≥90% of the authors. The panel of experts comprised physicians 
with broad experience in hymenoptera venom allergy working 
in one of the main allergy centers. Some centers started 
administering VIT in the early 1980s.
Hymenoptera Venom Allergy: 
Epidemiology and Clinical Picture
Hymenoptera
The insects of the order of Hymenoptera comprise aculeate 
species whose venom can trigger allergic reactions in humans. 
These reactions range from relatively mild reactions to fatal 
anaphylaxis [3]. In Europe, hymenoptera causing allergic 
reactions belong to the Apidae and Vespidae families or, 
sporadically, to Formicidae (Formica rufa) [4] and Myrmicinae 
(Solenopsis invicta) [5], which are widespread in North and 
Central America and in Australia.
The Apidae family includes the subfamilies Apinae 
(Apis mellifera) and Bombinae (Bombus terrestris, agrarum, 
medics), while the Vespidae family is composed of the Vespinae 
subfamily, including the genera Vespula (germanica, vulgaris), 
Dolichovespula (maculata, arenaria, saxonica, media), and 
Vespa (crabro, orientalis velutina var nigrithorax) and the 
subfamily Polistinae, which includes the genus Polistes 
(dominula, gallicus).
The bees and vespids of the genus Vespula are widespread 
in the far northern regions of Europe. In southern Europe, in 
addition to Vespula, hornets are a frequent cause of allergic 
reactions (genus Vespa), including the most widespread species 
Vespa crabro and some species of Polistes, such as Polistes 
dominula [6]. The genus Dolichovespula has a more limited 
diffusion and can be considered similar to Vespula from an 
allergological point of view.
In 2005, Vespa velutina nigrithorax, which is from 
Southeast Asia, was detected in the South of France. Vespa 
velutina is a predator of bees and is rapidly spreading from 
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France to neighboring countries. Anaphylactic reactions have 
been reported after Vespa velutina stings, with a variable degree 
of cross-reactivity with other vespids [7].
Given its low aggressiveness, allergy to bumblebees 
concerns a limited number of persons, in particular 
professionally exposed individuals [8], and should therefore 
be investigated on the basis of a detailed clinical history, 
provided that a suitable extract is commercially available for 
diagnosis. Immunotherapy with honeybee venom alone may 
be sufficient in non–professionally exposed bumblebee-allergic 
patients with primary sensitization to bee venom, whose 
reaction is most likely due to cross-reactivity. In occupationally 
exposed patients, who are frequently stung by bumblebees, 
immunotherapy should be with purified bumblebee venom 
(when available) [9].
Although difficult, recognition of the stinging insect 
remains crucial in the management of allergic reactions and 
is an integral part of the diagnosis in that it helps us to select 
specific immunotherapy; thus, information on the behavior 
and morphological characteristics of the culprit insects make 
for an accurate clinical history and diagnosis.
A mellifera has a characteristic serrated sting which remains 
stuck in the tissue together with the venom sack. The bee dies 
by self-evisceration when flying away from the victim. The 
vespids and other apids (bumblebees), on the other hand, have 
smooth stings, which can be extracted from their victims, thus 
enabling them to sting several times consecutively.
Epidemiology
Depending on the living environment and type of activity, 
56%-94% of the adult population are estimated to have been 
stung by a hymenoptera insect at least once in their lifetime; 
in Europe, this is by a bee in about one-third of cases [10]. As 
a consequence, the development of specific IgE to 1 or more 
venom allergens can occur as an ancestral defense response 
against the toxic effects of venom [11]. Such a response may 
be favored by atopic diathesis and genetic factors and may 
correlate with a high level of total IgE [10,12].
The prevalence of asymptomatic sensitization is estimated 
to range from 9.3% to 40.7% in the adult population, with 
higher proportions in cases of high exposure, for example, 
beekeepers (30%-60%) [13,14].
Epidemiological studies report wide variability in the 
prevalence of allergic reactions: repeated exposure to stings 
(studies on beekeepers) increases the prevalence of a large local 
reaction (LLR) by as much as 38% [15] and that of systemic 
reactions by 30%-45% [16,17]. 
In Europe, the prevalence of systemic reactions in the adult 
general population is 0.3%-8.9% [10,18], which increases to 
14%-32% among beekeepers [13]. Taking into account studies 
on anaphylaxis as a whole, hymenoptera stings are responsible 
for 7.3%-59% of cases, depending on the populations 
investigated, and are more frequent in adults [15].
According to data from the European Anaphylaxis 
Registry, out of 3333 diagnosed cases, hymenoptera venom 
allergy was the most frequent cause of severe reactions in the 
adult population (48.2%) [19].
Data from emergency departments in several parts of the 
world show that hymenoptera venom allergy is responsible 
for 1.5%-34% of anaphylactic reactions, with the lowest 
prevalence recorded in urban hospitals [10].
Recent Italian studies on cases of anaphylaxis reported 
directly by emergency departments to allergy centers for 
diagnostic assessment have shown that hymenoptera venom 
allergy is the most frequent cause (42%-70% of cases) [20,21].
Hymenoptera venom allergy is responsible for about 20% 
of the total cases of fatal anaphylaxis in several countries [10]. 
Death is due to shock with multiple organ failure within 10-15 
minutes of the sting and, in a quarter of cases, edema of the 
glottis [22].
Overall, the incidence of mortality in various European 
countries is between 0.03/million/year in Italy and 0.48 in 
France. In Italy, ISTAT data for the period 1994-2003 show 
94 deaths [15]. Mortality data are generally underestimated, 
as deaths are likely to be attributed by mistake to other causes, 
in particular cardiac disorders [10].
Since 40% of cases of fatal anaphylaxis occur as a first 
reaction to hymenoptera venom, it is important to carefully 
evaluate the risk factors that may cause a transition from 
asymptomatic sensitization to a more severe clinical 
manifestation [10,23-26].
Clinical Aspects
Hymenoptera venom is a mixture of various components, 
including bioactive molecules such as histamine, serotonin, 
tyramine, catecholamines, low-molecular-weight peptides 
(including mastoparans, kinins, and chemotactic peptides), 
and high-molecular-weight proteins (including phospholipase, 
hyaluronidase, mellitin, antigen 5), which differ by species 
and can act as allergens and, in some cases, cause toxic 
reactions. 
Table 1. Levels of Evidence and Grade of Recommendation [2] 
Level of Evidence
Level I Systematic reviews, meta-analysis,  
 randomized control trials
Level II Two groups, nonrandomized studies  
 (eg, cohort, case-control)
Level III One group nonrandomized  
 (eg, before and after, pretest and posttest)
Level IV Descriptive studies that include analysis  
 of outcomes (single-subject design, case series)
Level V Case reports and expert opinion that include  
 narrative literature, reviews, and consensus  
 statements
Grade of Recommendation
Grade A Consistent level I studies
Grade B Consistent level II or III studies  
 or extrapolations from level I studies
Grade C Level IV studies or extrapolations from  
 level II or III studies
Grade D Level V evidence or troublingly inconsistent  
 or inconclusive studies at any level
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From a clinical point of view, we can distinguish between 
local reactions, LLRs, systemic allergic reactions, toxic 
systemic reactions, and unusual reactions. 
In most cases, local reactions consist of itching, erythema, 
and edema of limited extension; they are transient, normal 
consequences of the vasoactive and inflammatory action of 
some venom components. In the event of allergy, more severe 
large local reactions may occur, and these are characterized 
by delayed and prolonged inflammation and edema increasing 
within 24-48 hours and resolving in 3-10 days, with an average 
extension exceeding 10 cm in diameter.
The anaphylaxis guidelines of the World Allergy 
Organization [27] and of the European Academy of Allergy 
and Clinical Immunology (EAACI) [28] have established 
clinical criteria for the diagnosis of anaphylaxis, confirming 
the proposal of the second symposium on the definition and 
management of anaphylaxis summary report - Second National 
Institute of Allergy and Infectious Disease/Food Allergy and 
Anaphylaxis Network Symposium [29]. 
Various classifications of the grade of severity of reactions 
have been proposed, those of Mueller [30] and Ring and 
Messmer [31] being the most frequently referred to. Both 
classifications have limitations: that of Mueller does not take 
into account the possible absence of cutaneous symptoms and 
the possibility that an isolated cardiovascular shock might be 
the only allergic sting-induced manifestation [29], while that of 
Ring and Messmer is almost entirely focused on cardiovascular 
collapse, which is considered more severe than respiratory 
impairment.
The classification of mild, moderate, and severe reactions 
of Brown [32] can also be adapted to systemic allergic reactions 
to hymenoptera venom [33]. EAACI recently proposed 
a simplification of the severity criteria for acute allergic 
reactions, dividing them into local (grade 1) and systemic 
(grades 2 and 3) [34]. 
Skin symptoms are the most frequent manifestation (80%) 
and represent the only manifestation in 15% of cases of 
systemic reactions in adults. Some cases are characterized 
by onset of chronic urticaria and cold urticaria after the 
sting, generally without an immediate reaction and with an 
unknown risk for systemic reactions to re-sting. Almost 50% of 
systemic reactions include respiratory symptoms (upper airway 
angioedema). Symptoms and signs of hypotension may appear 
in over 60% of adults; in half of the cases, these occur with loss 
of consciousness. Cardiac involvement during anaphylaxis can 
cause bradycardia, arrhythmias, and acute coronary syndromes, 
thus making it compatible with Kounis syndrome [35,36]. It can 
also be secondary to decreased venous return, which is in turn 
due to histamine-induced vasodilatation, and permeabilization. 
Gastrointestinal symptoms (abdominal pain, nausea, vomiting, 
and diarrhea) and uterine cramps with possible miscarriage 
may occur, as may neurological symptoms (eg, convulsions). 
Biphasic anaphylaxis, which is characterized by recurrence 
of anaphylactic symptoms within 4-12 (exceptionally 72) 
hours [37] after resolution (without re-exposure), was reported 
in 0.4%-14.7% of cases [38]. 
Toxic systemic reactions are caused by the action of venom 
components with enzymatic activity and organ-specific toxicity 
and usually occur after multiple simultaneous stings (from 
several tens to several hundreds). Toxic effects occur in hours to 
days and consist of rhabdomyolysis, intravascular hemolysis, 
coagulation disorders, liver damage, and acute renal failure. 
Fatal cases are uncommon [39].
Unusual reactions are rare and are caused by a toxic or 
non–IgE-mediated immunological mechanism, in some cases 
by autoimmunity. These can occur within hours to days of a 
single sting and include serum sickness–like manifestations, 
central nervous system manifestations (acute encephalopathy, 
Guillain-Barré syndrome, myasthenia, peripheral neuritis), 
hematological reactions (thrombocytopenic purpura, Henoch-
Schönlein purpura, hemolysis, coagulation disorders), 
muscle reactions (rhabdomyolysis), renal reactions (acute 
renal failure due to interstitial nephritis or tubular damage, 
nephrotic syndrome), and respiratory reactions (alveolar 
hemorrhage) [40]. Metrorrhagia after a bee sting is unusual [41]. 
Pediatric Aspects
The prevalence of asymptomatic sensitization was 
reported to be 3.7% in an Italian pediatric case study [42]. The 
prevalence of LLRs has been reported to be between 0.9% [43] 
and 20.8% [44]; the prevalence of systemic reactions is below 
1% [15,42].
According to the European Anaphylaxis Registry, 
hymenoptera venom allergy is the second cause of severe 
reactions in children (20.2%) after food allergy [19].
Risk factors for severe systemic reactions after hymenoptera 
stings in children were evaluated by Graif et al [45] in a 
population of adolescents aged 13-14 years. Atopic children 
had a significantly higher rate of severe reactions than 
nonatopic children (36.9% vs 24.8%). Therefore asthma, 
allergic rhinitis, and atopic eczema should be considered risk 
factors for reactions of any severity; moreover, the severity 
of the reaction is also associated with the severity of asthma. 
Atopy was confirmed as a risk factor for severe reactions in 
a more recent study [46]. However, this finding should be 
confirmed in larger pediatric populations.
In children, systemic reactions mostly affect the skin and 
rarely the cardiovascular system. Skin symptoms are the only 
clinical manifestation in 60% of cases [47].
Children have a favorable prognosis regarding re-sting, both 
in studies based on sting challenge [48] and field sting [49,50].
Treatment of Acute Reactions
In the Hospital Setting
Treatment of anaphylactic reactions in the hospital 
setting should adhere as closely as possible to guidelines. 
After discharge, the patient should be referred to an allergy 
specialist and prescribed adrenaline autoinjectors [51-53]. As 
for postanaphylaxis monitoring, WAO guidelines indicate a 
minimum of 8-10 hours to cover the risk of late anaphylactic 
reactions [27]. American guidelines [54] suggest individualizing 
this period, whereas the EAACI guidelines [28] advise a 
minimum duration of 6-8 hours for patients with respiratory 
symptoms and 12-24 hours in the event of hypotension or 
collapse.
The expert panel believe that, after appropriate therapy and 
complete resolution of the clinical picture, the patient should 
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be kept under observation and monitored for at least 6-8 hours 
up to 24 hours depending on the severity and characteristics of 
the reaction at onset, comorbidity, and risk factors (strength of 
recommendation, D). The duration of this period may depend 
on the internal regulations of the individual hospital.
Management of anaphylaxis in the hospital setting requires 
general measures and the administration of specific medicinal 
products [27].
General measures include the following: (a) Monitoring 
of vital parameters. (b) Positioning of the patient in the 
Trendelenburg position (supine with legs raised 10°-15°) 
or, in the case of vomiting, on the right side. If the patient is 
pregnant, she should be placed in the supine position to gently 
dislodge the fetus to the left so as to decompress the inferior 
vena cava and thus improve venous return to the heart; if she 
is laid on one side, it should be the left. (c) Rapid cannulation 
of a peripheral venous access with a high-gauge needle (at 
least 18 G). (d) Rapid intravenous administration of isotonic 
saline solution (plasma expanders should be avoided owing 
to the risk of mast cell degranulation). (e) Administration of 
oxygen (if necessary); in the case of pregnancy, oxygen should 
be administered to avoid fetal hypoxemia (4 L/min using nasal 
prongs). (f) Continuous clinical and instrumental monitoring 
of the patient (arterial blood pressure, heart rate [bradycardia 
in hypotension seems to have a negative prognostic value], 
and peripheral oxygen saturation).
The specific medicinal products used in the management 
of anaphylaxis are as follows:
– Adrenaline: Adrenaline is the treatment of choice 
for anaphylaxis regardless of the presence of shock 
(strength of recommendation, C) [27-29,55,56]. It 
slows the progression of symptoms and can prevent 
the development of fatal or biphasic reactions (strength 
of recommendation, C) [57,58]. If the correct dosage 
is administered, it can be used without absolute 
contraindications in pediatric and geriatric populations 
and in patients with heart disease [28,59,60], except for 
some conditions, such as long QT syndrome (in this 
case, adrenaline should be administered with extreme 
caution, in the case of real need, and in the presence of 
the cardiologist). 
 Adrenaline is also the drug of choice for the treatment 
of anaphylaxis in pregnant women (strength of 
recommendation, D) [61-63]; in fact, ephedrine may have 
a lower risk of uterine contractions, although if it proves 
inefficacious, it may cause escalation of the anaphylactic 
reaction, with the consequent risks.
 Adrenaline should be administered intramuscularly in 
the lateral thigh (vastus lateralis muscle) at a dose of 
0.01 mg/kg of a 1/1000 solution, with a maximum dose 
of 0.3 mg in children and 0.5 mg in adults [27]. The dose 
may be repeated after 5-15 minutes if necessary (strength 
of recommendation, B) [27,59].
 Intravenous administration should be reserved for the 
most severe cases, with imminent danger of life for 
cardiovascular collapse (strength of recommendation, D) 
[56,64]. The infusion should be stopped 30 minutes after 
clinical stabilization. Table 2 describes the modalities 
and the concentrations of intravenous adrenaline.
– Dopamine: Dopamine should be used if it is not possible 
to maintain stable circulatory function with adrenaline. 
The dosage is 5-15 µg/kg/min. Table 3 shows the hourly 
infusion rate using a syringe pump for the desired 
dosages based on body weight.
– Antihistamines: The use of anti-H1 is recommended 
only for the treatment of skin symptoms (strength 
of recommendation, B) [28,65,66]. There are no 
controlled studies to support the use of antihistamines 
for the treatment of anaphylaxis [67]. Intravenous 
administration has the advantage of acting more quickly, 
although it should be performed very slowly to avoid 
adverse effects (including hypotension). The suggested 
dose is generally 10 mg of chlorpheniramine in adults 
and 2.5-5 mg in children [27].
 The concomitant administration of anti-H2 antihistamines 
has not proved to have greater therapeutic efficacy and 
is therefore not recommended in guidelines.
– Corticosteroids: Corticosteroids are used for 
the control of bronchospasm and prevention of 
biphasic reactions [28,54,59,65], even if there are no 
controlled studies to confirm their effectiveness in the 
treatment of acute anaphylactic reaction (strength of 
recommendation, D) [68]. The recommended drugs are 
intravenous hydrocortisone 200 mg in adults (in children 
up to 100 mg) or intravenous methylprednisolone 
Table 2. Intravenous Administration of Adrenaline
Bolus
1 ampoule diluted to 10 mL (100 µg/mL) → 0.5 mL (=50 µg) 
in bolus or syringe pump 
1 ampoule diluted to 50 mL (20 µg/mL) → 180 mL/hour for 
1 minute
Infusion in syringe pump
1 ampoule of 1 mg, diluted to 50 mL with saline solution  
speed = 20 µg/mL
Infusion rate in syringe pump: 
 5 µg/min 15 mL/h 
 10 µg/min 30 mL/h 
 15 µg/min 45 mL/h
Table 3. Dopamine: Hourly Rate of Administration Based on Body Weight 
and Desired Dosagea
Body       5 μg/kg/min         10 μg/kg/min          15 μg/kg/min 
 μg/min mL/h μg/min mL/h μg/min mL/h 
40 200 1.50 400 3.00 600 4.50
50 250 1.87 500 3.75 750 5.62
60 300 2.25 600 4.50 900 6.75
70 350 2.62 700 5.25 1050 7.87
80 400 3.00 800 6.00 1200 9.00
90 450 3.37 900 6.67 1350 10.12 
a200-mg ampoule: 2 ampoules in 5% glucose solution administered 
using a 50-mL syringe pump (=8000 μg/mL).
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of administration than the syringe-based system. However, 
a recent study showed that the bioavailability of adrenaline 
administered using a syringe-based autoinjector is not affected 
by needle length [78]. 
In the pediatric population, considering the fixed dosages of 
the autoinjector, there is a risk of administering a lower or higher 
dose, depending on body weight [59,79]. In children weighing 
15-30 kg, a lower dose should be used if the anaphylactic 
reaction is not severe; an adult dose should be administered if the 
anaphylaxis is severe or the patient has concomitant bronchial 
asthma (risk factor for fatal anaphylaxis) [80].
Table 5 shows the symptoms and signs indicative of an 
anaphylactic reaction to ensure that the patient knows when to 
administer adrenaline; this table can be provided to the patient 
during training with the device.
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Table 4. Doses of Glucagon to Be Administered During Anaphylaxis
Glucagon Dosage Syringe Pump Infusion Speeda 
1 mg/h 50 mL/h
2 mg/h 100 mL/h
3 mg/h 150 mL/h
4 mg/h 200 mL/h
5 mg/h 250 mL/h
a1-mg ampoule, diluted to 50 mL with saline solution = 0.02 mg/mL.
Table 5. Criteria for the Diagnosis of Anaphylaxis [27] 
Naive patient
Acute onset (minutes or hours) of cutaneous and/or mucosal 
symptoms (pruritus, flushing, lips-tongue-uvula swollen, hives 
and generalized urticaria) 
+
One or more of the following:
 A. Respiratory symptoms (dyspnea, wheezing,  
  bronchoconstriction, stridor, reduced peak expiratory  
  flow, hypoxemia)
 B. Decreased blood pressure and/or associated symptoms of  
  the target organs (hypotonia, collapse, syncope,  
  incontinence) 
These criteria allow the diagnosis of about 80% of cases of 
anaphylaxis, as cutaneous symptoms are present in 80% of 
anaphylactic reactions 
After exposure to a likely allergen
Two or more of the following:
 A. Cutaneous and/or mucosal symptoms (pruritus, flushing,  
  lips-tongue-uvula swollen,  hives and generalized  
  urticaria)
 B. Respiratory symptoms (dyspnea, wheezing,  
  bronchoconstriction, stridor, reduced peak expiratory  
  flow, hypoxemia)
 C. Decreased blood pressure and/or associated symptoms of  
  the target organs (hypotonia, collapse, syncope,  
  incontinence) 
 D. Persistent gastrointestinal symptoms (abdominal pain,  
  cramps, vomiting)
After exposure to a known allergen
Reduction in blood pressure:
 A. Infants and children:
  <70 mmHg from 1 mo to 1 y  
  <70 mmHg (+2 × y) from 1 to 10 y
  <90 mmHg from 11 to 17 y
 B. Adults:
  <90 mmHg or a decrease >30% from baseline values
50-100 mg in adults (in children 1 mg/kg, maximum 
50 mg) [27].
– Glucagon: Glucagon exerts both positive inotropic and 
chronotropic effects for activation of adenylyl cyclase 
activity independently of the ß receptor. It is sometimes 
needed in patients taking a ß-adrenergic blocker who 
have hypotension and bradycardia and who do not 
respond optimally to adrenaline. Glucagon can be 
administered intravenously in adult patients at a dose 
of 1 mg as an initial intravenous bolus; the dose can 
be repeated every 5 minutes and increased to 3-5 mg 
if necessary. Continuous infusion in a syringe pump 
should be at 1-5 mg/h (strength of recommendation, D) 
(Table 4). It should be pointed out that glucagon is an 
off-label drug for the therapy of anaphylaxis and can lead 
to severe vomiting and hyperglycemia [69,70].
– Desmopressin: Desmopressin can be used for the 
treatment of anaphylactic shock that is unresponsive to 
adrenaline (strength of recommendation, D) [71,72].
– Bronchodilators: Inhaled short-acting formulations 
(eg, salbutamol) are preferred.
Self-treatment 
All patients with a history of anaphylactic reaction should 
be provided with adrenaline autoinjectors to be injected into 
the vastus lateralis muscle [27,28,73]. Currently available 
autoinjectors differ from country to country [74]. In obese or 
overweight patients, the reduced length of the needle does not 
always ensure intramuscular administration [75,76]; therefore, 
the patient should be advised to press the autoinjector well 
into the thigh fat to compress it and allow the adrenaline to 
penetrate the muscle. 
One study compared 3 adrenaline autoinjectors for 
penetration depth in ballistic gelatin, namely, 2 cartridge-
based devices (EpiPen and Jext) and 1 syringe-based device 
(Anapen) [77]. For the 2 cartridge-based systems, the mean 
(SD) maximum injection depth in gelatin within 10 seconds 
was 29.68 (2.08) mm for EpiPen and 28.87 (0.73) mm for 
Jext; for the syringe-based system (Anapen), the depth was 
18.74 (1.25) mm. Cartridge-based systems therefore reached 
a depth that was double the length of the needle. The same 
study also showed that the average depth of the adipose tissue 
in 50 females was 14.8 mm. Comparison of the robustness 
and performance of these 3 devices revealed that cartridge-
based systems are more robust and ensure greater speed, 
validity, correctness of the dose, and accuracy of the site 
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Although many patients are afraid to use their adrenaline 
autoinjector for fear of adverse effects [81], no significant 
adverse effects have been reported, with the exception of 
the known onset of tachycardia, tremors, and peripheral 
vasoconstriction [82].
Even if adrenaline remains the first-choice drug in 
anaphylactic reactions, the patient with mild systemic reactions 
(eg, only hives) may also self-treat with oral corticosteroids 
(eg, methylprednisolone tablets 16 mg = 4 tablets) and a double 
dose of second-generation antihistamines.
Indications for the Prescription of Adrenaline 
Autoinjectors
Adrenaline autoinjectors should be prescribed to the 
following groups of patients [28,33,73,74]:
– Children and adults with systemic reactions more severe 
than systemic skin reaction or with a high risk of re-
exposure to stings (eg, beekeepers), before VIT (level 
of evidence IV, strength of recommendation C).
– Children and adults undergoing VIT, but with risk factors 
for incomplete clinical protection (very severe onset 
reaction, adverse reactions during immunotherapy, lack 
of sting protection during VIT, bee venom allergy) (level 
of evidence V, strength of recommendation D).
– Children and adults who have discontinued VIT but 
present risk factors for incomplete clinical protection (eg, 
particularly severe pre-VIT systemic reaction, systemic 
reaction caused by VIT, lack of protection during VIT) 
(level of evidence V, strength of recommendation D).
– Children and adults with elevated levels of serum mast cell 
tryptase or mast cell disorders and a history of systemic 
reaction to hymenoptera sting, independently of VIT (level 
of evidence IV, strength of recommendation D).
– Children and adults who discontinued VIT, despite 
having mast cell disorders and/or elevated levels of 
serum mast cell tryptase (level of evidence IV, strength 
of recommendation C).
According to European guidelines, the prescription 
of 2 adrenaline autoinjectors is recommended in patients 
with mast cell disorders and/or elevated levels of serum mast 
cell tryptase, and in patients with a history of very severe 
anaphylactic reactions who required the administration of 
multiple doses of adrenaline or who do not have rapid access 
to hospitals [28]. Based on currently available data [83], the 
expert panel considers basal tryptase levels above 7.95 μg/L as 
high in those patients with a history of anaphylactic reaction 
caused by hymenoptera sting with loss of consciousness and 
no cutaneous/mucosal involvement.
The expert panel also suggests prescribing 2 adrenaline 
devices to obese patients, as the injection might not reach the 
muscle and could therefore prove less effective.
Regarding LLRs, the risk of a systemic reaction is not 
currently considered so high as to require the prescription of 
adrenaline [74]. Nevertheless, Italian experts do not rule out the 
possibility of prescribing adrenaline to patients at risk of multiple 
stings (eg, beekeepers) and to those who had a single LLR, since 
in these patients the risk of a subsequent systemic reaction to a 
re-sting cannot be completely excluded compared with patients 
who have already experienced repeated LLRs [84,85].
European Medicines Agency Provisions on 
Adrenaline Autoinjectors 
After evaluation of all available data, the European 
Medicines Agency (EMA) confirmed that intramuscular 
administration is the most indicated route for obtaining a rapid 
response in the treatment of anaphylaxis [86].
The EMA observed that correct administration of 
adrenaline by autoinjectors is affected by several factors 
such as needle length, thickness of subcutaneous fat, mode of 
operation of the autoinjector (whether spring-loaded and/or 
cartridge-based), angle with which it is placed into the skin, 
force used to activate it, and the patient’s ability to follow the 
instructions properly.
Healthcare professionals are recommended to 
prescribe 2 autoinjectors, which patients should be advised 
to carry with them at all times, and to instruct the patient on 
how to use the autoinjector through educational material and 
practical training. 
Diagnostic Criteria
Diagnosis is based on the classification of the type of reaction, 
confirmation of IgE-mediated pathogenesis, and identification 
of the stinging insect. On this basis, the clinical history and the 
results of in vivo and in vitro tests are crucial [3,87].
The history includes the description of the symptoms and of 
the course of the reaction (possibly documented by a medical 
report), the number of stings, the characteristics of the culprit 
insect (where possible), and the identification of specific risk 
factors for the severity of reaction [3].
It may be useful to show the patient an entomological notice 
board to facilitate the identification of the stinging insect; 73% 
of Vespula-allergic patients accurately identify this kind of 
hymenoptera on the board [88].
Since it is possible to document sensitization to venom in 
10%-30% of patients with a negative history, only those with 
a history of previous systemic reaction [3,33,87,89] should be 
investigated. Table 6 shows the indications for performance 
of diagnostic tests.
186
Table 6. Indications for Performing Diagnostic Tests
Indicated 
- In patients with a history of systemic reaction following 
hymenoptera stings
Not indicated:
- In persons with a positive family history for allergic reaction 
to hymenoptera stings
- In persons who have an unjustified fear of developing a 
systemic reaction to hymenoptera stings following news of 
fatal anaphylaxis in the media
- As screening in the general population
Optional:
- In patients with a history of large local reactions
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In patients with a history of LLR, skin tests (as well as 
determination of specific IgE) may be considered optional, at 
the discretion of the clinician in specific cases, for example 
in patients at a greater risk of re-sting with recurrent and 
bothersome LLRs (eg, beekeepers, farmers), who could benefit 
from immunotherapy [90]. 
Skin tests are the gold standard for diagnosis and should 
be carried out at least 2 weeks after the last sting to exclude a 
false-negative response during the refractory period [3,33,87]. 
As this period may be even longer, tests yielding negative 
results in persons with a suggestive history should be repeated 
after 1-2 months. Conversely, in some patients, sensitization can 
only be demonstrated during the first week after the reaction [91].
European guidelines suggest performing skin tests 
gradually, that is, prick tests first, followed, if negative, 
by intradermal tests [3,33,87]. Intradermal tests should be 
performed even in cases of a positive prick test result in order 
to correctly identify a cutaneous endpoint for follow-up of VIT. 
Correct performance of skin tests with hymenoptera venom 
is of crucial importance, both to ensure an accurate diagnosis 
and to monitor VIT [92]. In particular, intradermal tests 
should be carried out with 0.02 mL of the allergenic extract 
injected into the dermis to generate a wheal of approximately 
3 mm in diameter. The reading should be performed after 
15-20 minutes; a positive result is defined as an increase of at 
least 3 mm in the average diameter of the initial wheal, with 
associated erythema. A morphological score should be used 
to enable comparison of the results. This consists of drawing, 
on transparent cellophane, the area injected and the area of the 
reaction after 15-20 minutes [93].
The prick test is carried out at 100 µg/mL. Intradermal 
testing can start from very low concentrations, according to 
the symptoms presented by the patient; concentrations ranging 
from 0.001 to 1 µg/mL are normally used.
The sensitivity of the prick test is lower than that of the 
intradermal test. In a study performed on 301 patients allergic 
to Vespula species venom, prick testing identified 49% of 
cases, while the combination of prick and intradermal reaction 
facilitated a diagnosis in 94% of cases [94]. Intradermal testing 
with nondialysate venoms can be irritating at concentrations 
higher than 1 µg/mL [95]. In Europe, standardized venoms of 
A mellifera, Vespula species, Polistes species, and V crabro 
are currently available; the venoms of Vespula and Polistes 
consist of a mix of clinically relevant species (Vespula species: 
V vulgaris, V flavopilosa, V germanica, V maculifrons, 
V pennsylvania, and V squamosa; Polistes species [American]: 
P annularis, P exclamans, P fuscatus, and P metricus). Because 
of low cross-reactivity between European and American 
P venoms [96], extracts of P dominula are now available for 
both diagnosis and VIT [97]. On the other hand, high cross-
reactivity between Vespula species venom and V crabro has 
been confirmed [98]. A recent study [99] suggested that, in 
patients with a proven reaction to V crabro, VIT with V crabro 
venom may have a higher safety profile.
Skin tests with venoms are generally safe, even in patients 
with mastocytosis [100,101]. One study highlighted safety, 
even if the tests are carried out simultaneously at different 
concentrations [102]. The Italian expert panel considered that 
available data are insufficient and recommended a preliminary 
step where the same concentration of several venoms is 
simultaneously used for skin testing. A higher concentration 
should only be used after reading the reactions to the first set. 
This caution is to be maintained, especially in patients with 
severe anaphylactic reaction or mast cell disorders.
The total IgE dosage may help to ensure correct 
interpretation of specific IgE values, especially if they are 
very low [103]. In the event of very high levels, the presence 
of concomitant pollinosis should be investigated.
Serum specific IgE can be detected immediately after the 
sting, even if the best period for its determination is 1-4 weeks 
after the sting [3].
The sensitivity of serological tests using whole extracts is 
generally lower than that of skin tests. In general, in vitro tests 
for determination of specific IgE to the whole venom extract 
can be negative in up to 20% of patients with positive skin test 
results, whereas approximately 10% of patients with negative 
skin test results are positive in the in vitro test. Therefore, 
guidelines suggest performing both tests [3,33,87,104].
The sensitivity of serological tests for Vespula species 
is lower than that of tests for bee venom: 98% to 100% for 
bee [105,106] and 83% to 97% for Vespula [105,106]. A 
new in vitro method enriched with the recombinant allergen 
Ves v proved more sensitive than traditional methods [94]. 
Furthermore, it has recently been hypothesized that negative 
skin test results with A mellifera extract may be due to a minor 
presence or even absence of some allergens in diagnostic and 
therapeutic extracts [107]. It is to be noted that the values of 
serum specific IgE to V crabro venom may vary according to 
the laboratory method used.
Diagnosis is complicated by sensitization to multiple 
venoms in patients who have not identified the stinging 
hymenopteran. The double positivity to venom of A mellifera 
and Vespula species is found in 25%-40% of cases and may be 
due to double sensitization, cross-reactivity between epitopes 
present in both venoms (hyaluronidase; Api m 5 and Ves v 3; 
Api m 12 and Ves v 6), and cross-reactive carbohydrate 
determinants (CCDs). The commercial availability of some 
major allergens expressed in recombinant form enables 
implementation of component-resolved diagnosis (CRD) 
[103,108]. 
Bee venom–allergic patients often have a broad sensitization 
profile. Api m 1, the most relevant allergen of bee venom, is 
not sensitizing in up to 43% of cases [109]. The combination 
of 2 allergens (Api m 1 and 10) enables diagnosis in 86.8% 
of cases; the combination of 6 allergens (Api m 1- 5, Api 
m 10) has a sensitivity of 94.4% [109]. Currently marketed 
recombinant allergens include rApi m 1, rApi m 2, rApi m 3, 
rApi m 5, and rApi m 10. Patients with allergy to Vespula 
venom are sensitized mainly to Ves v 1 and Ves v 5. The 
combined search of specific IgE toward these 2 recombinant 
allergens enables the identification of 92%-94% of Vespula-
allergic patients [110,111].
In Southern Europe, double Vespula-Polistes sensitization 
is more frequent than Apis-Vespula sensitization [112], 
and cross-reactivity between allergens of 2 species often 
poses diagnostic difficulties [113,114]. In cases of difficult 
interpretation between sensitization Vespula and sensitization 
to Polistes, the use of Ves v 5 and Pol d 5 seems to be 
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helpful in clinical practice, provided that the difference in 
specific IgE levels between the 2 molecules is particularly 
significant, with at least double values of one recombinant 
over the other [114-116]. Furthermore, where available, 
phospholipases (Pol d 1/Ves v 1) have proved useful in 
identifying the probable sensitizing species in Vespula/
Polistes–sensitized patients [114]. A new major allergen of 
the venom of P dominulus, Pol d 3 (dipeptidyl peptidase IV) 
has recently been identified, although it was found to be cross-
reactive with both Apis and Vespula venoms [117].
IgE to CCDs can explain multiple positive in vitro results; 
serum determination of CCDs (bromelain or MUXF3) allows 
for greater diagnostic accuracy [105]. Polistes venom is CCD-
free and is therefore not affected by this cross-reactivity [118].
Figures 1 and 2 show the diagnostic algorithm for cases 
of double-positive results with Apis-Vespula and Vespula-
Polistes.
In summary, CRD can be used to discriminate between 
primary sensitization and cross-reactivity in patients with 
double-positive results in diagnostic tests with whole extracts, 
thus enabling the specialist to choose the most suitable venom 
for VIT and to avoid treatment with double VIT. However, the 
decision should rely not only on CRD results, but should also 
take into account the severity of the reaction and the patient’s 
general health status. CRD may also help in the diagnosis of 
patients with a history of systemic reaction and negative results 
in standard diagnostic tests [119,120].
CAP-inhibition also makes is possible to distinguish 
between double sensitization and cross-reactivity, although 
it may be relatively expensive and its results could prove 
difficult to interpret [103]. It appears to be very useful in cases 
of double Vespula-Polistes cosensitization, when CRD cannot 
discriminate between different possibilities [114,115].
The basophil activation test (BAT) is the most widely 
used blood cell–based diagnostic test in Europe in selected 
situations. If performed in highly specialized laboratories, 
it can identify approximately two-thirds of patients with 
a positive history and negative skin and serological test 
results [121]. BAT is also recommended in patients with 
double-positive results and inconclusive in vivo or in vitro 
test results with recombinant allergens [119]. Since BAT 
results are influenced by the presence of venom CCDs, using 
CCD-free recombinant allergens ensures greater diagnostic 
accuracy [119,122]. The role of BAT as a diagnostic tool in 
patients with mast cell disorders and negative venom-specific 
IgE and skin test results remains controversial [123-126]. 
Sting challenge with a live insect should not be used for 
diagnostic purposes owing to the risk of potentially severe 
systemic reactions and its low negative predictive value [127].
In the presence of systemic reactions, basal serum tryptase 
levels should always be determined, as adults affected by 
mast cell disorders and/or elevated basal tryptase levels have 
a significantly greater risk of severe reactions to hymenoptera 
stings [16,128].
Moreover, patients should be investigated for mastocytosis, 
even in the absence of cutaneous manifestations compatible 
with mast cell disorders and increased tryptase levels, and in 
cases of severe anaphylactic reaction with syncope without 
urticaria and/or angioedema and a REMA score ≥2 [129]. High 
basal serum tryptase is not pathognomonic of mastocytosis 
and can also be found in hematological diseases (especially 
those of the myeloid lineage), end-stage chronic renal failure, 
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Figure 1. Diagnostic algorithm in honeybee and vespid venom allergy. 
CRD indicates component-resolved diagnosis; CCD, cross-reactive 
carbohydrate determinant.
Figure 2. Diagnostic algorithm in Vespula species and Polistes dominula 
venom allergy. CRD indicates component-resolved diagnosis; BAT, 
basophil activation test.
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onchocercosis in treatment, and abdominal aortic aneurysm 
(2 cases with anaphylaxis to hymenoptera venom were 
reported) [130].
Table 7 shows practical considerations in the diagnostic 
flow chart for hymenoptera venom allergies.
Pediatric Aspects
Diagnostic tools are no different from those used in adults. 
Furthermore, in children, the degree of skin sensitization does 
not correlate with the severity of the reaction [131].
Specific Immunotherapy
Definition and Mechanisms of Action
VIT is the therapy of choice for patients who develop a 
systemic reaction after hymenoptera sting, since it can induce 
tolerance to venom [33,73,132-134].
VIT consists of an induction phase and a maintenance phase. 
The induction phase involves subcutaneous administration of 
increasing doses of the venom extract up to the protective dose, 
ie, 100 μg. Protocols used for this purpose differ in length. The 
maintenance phase involves the administration of fixed amounts 
of venom at regular time intervals to maintain tolerance.
The mechanisms of action of immunotherapy are numerous 
and impact at both early and late stages. They include an 
increase in specific IgG1 and IgG4 levels [135-138], a 
cytokine shift characterized by reduction in IL-4 and IL-5 
and an increase in IFNγ [139-141], the reduced expression of 
adhesion molecules [142], lymphocyte downregulation [143], 
reduction of mast cell and basophil activation [144,145], 
immunomodulation by IL-10 [137,146-148], and induction 
of regulatory T cells [131,149,150].
Indications
VIT is indicated in the following circumstances: (a) 
children and adults with a systemic reaction involving organs 
other than the skin [90]; (b) systemic skin reactions in cases 
of high risk of exposure and/or impaired quality of life [151] 
in adults [90]; (c) patients with clonal mast cell disorder and a 
history of a systemic reaction [152], even though sensitization 
can be weak or sometimes transitory.
Information on children with cutaneous-mucosal reactions 
is provided in the appropriate section.
VIT is not generally indicated in cases of LLR, as the risk of 
progression in systemic reactions is low (2%-7%) [89,153,154], 
especially if the LLRs are recurrent [84,89]. The clinical efficacy 
of VIT can be seen in the fact that it reduces the extent of 
consecutive LLRs [155,156]. Its use is not contraindicated in 
patients with recurrent and severe LLRs. VIT is not indicated 
unusual reactions (ie, serum sickness–like manifestations, 
central nervous system manifestations, and hematological, 
muscle, and renal reactions), where the mechanism of action 
is unclear [73].
Clinical Efficacy
Specific subcutaneous immunotherapy for hymenoptera 
venom is the only treatment able to protect patients from 
systemic reactions after subsequent stings [90]. Numerous 
studies have evaluated the efficacy of VIT, both with sting 
challenge and field sting. In a recent Cochrane Review, 
the percentage of nonprotection was 2.7% in treated 
patients compared with 39.8% in patients not undergoing 
immunotherapy [156]. Regarding vespid venom, protection 
is between 91% and 96%, while for bee venom it ranges 
between 77% and 84% [14,90,157-167]. Studies performed 
on European populations, including Italian cases, show that 
about 70% of treated patients are allergic to vespids [164,166].
The different methods of preparation of the extracts do not 
affect their protective capacity; the efficacy of purified aqueous 
and aluminum hydroxide–adsorbed preparations (the so-called 
depot preparations) is in fact comparable [168]. 
As for VIT with Polistes venom, the use of P dominula 
venom to treat European patients should be preferred, since 
American Polistes venom extracts have been reported 
to lack a protective effect [6,169]. However, a recent 
study [170], in which incomplete in vitro cross-reactivity 
was confirmed, did not detect differences in clinical 
protection between VIT with a mixture of American Polistes 
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Table 7. Allergological Diagnosis in Hymenoptera Venom Allergy: Practical 
Considerations
– Skin tests represent the diagnostic gold standard and should 
be performed at least 2 weeks after the sting; if negative, they 
should be repeated after 1-2 months.
– Prick tests, even if positive, should be integrated with 
intradermal tests.
– Simultaneous testing of the same concentration of more 
venoms is to be preferred. The next concentration should 
only be tested afterwards.
– Skin tests with venoms are generally safe, even in patients 
with mastocytosis, if performed by trained personnel in a 
suitable environment.
– Validated methods are to be used for the determination of 
serum specific IgE to venom allergens.
– There is no correlation between the severity of a reaction and 
the scores of in vivo and in vitro diagnostic tests.
– The use of component-resolved diagnosis (CRD) is indicated 
in cases of polysensitization or negative allergy tests in 
patients with a proven history of previous systemic reaction.
– At present, CRD makes it possible to distinguish between 
allergy to Apis mellifera and allergy to Vespula species 
venoms; the value of CRD is limited in cases of double 
positivity to Vespula-Polistes.
– The CAP-inhibition method is appropriate in cases of double 
positivity to Vespula-Polistes, when CRD is not valid.
– The basophil activation test should be carried out in highly 
specialized laboratories for diagnostic purposes, only in 
specific situations. Its role as a diagnostic tool in patients 
with mast cell disorders and negative venom-specific IgE and 
skin test results remains controversial.  
– When a severe systemic reaction occurs, baseline serum 
tryptase levels should be measured.
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and VIT with P dominula after field sting. Further studies 
are necessary to confirm these data. 
Table 8 describes known risk factors for reduced efficacy 
of VIT.
Protocols
Over the years, various induction protocols have been 
proposed with the aim of reducing the incidence of adverse 
effects while rapidly achieving clinical protection and 
favoring adherence. According to the chosen protocol, the 
maintenance dose may be reached in a few weeks, a few days, 
or a few hours [33,73,171]. Conventional and “clustered” 
protocols do not significantly differ from one another as far 
as safety is concerned [172]. Ultrarush induction protocols 
have proved effective [173-175], inducing early changes in 
immunological parameters associated with the efficacy of VIT 
(IgE, IgG4) [176]. To increase adherence to VIT, management 
of immunotherapy protocols can be flexible, for example, by 
switching from an aqueous extract to a depot extract by the 
same manufacturer, with no impact on efficacy or safety [177].
The starting dose of VIT is between 0.001 μg and 0.1 μg; 
however, treatment can be initiated safely from 1-5 μg of venom 
using a rush protocol both in adults and in children [172, 178]. 
The maintenance dose of 100 μg is considered the gold standard 
in both adults and children and must be increased to 200 μg [179] 
in unprotected patients (usually adults) and, according to some 
authors, in beekeepers [13]. Once the maintenance dose has been 
reached, the intervals between doses should be maintained at 
4 weeks in the first year and gradually increased to 6-8 weeks 
in subsequent years, with no reduction in the clinical efficacy 
of VIT [180]. According to some authors [181-183], after the 
third year of VIT, the interval can be progressively lengthened 
up to 12 weeks. Other studies evaluated 6-month intervals; this 
extension is not currently recommended because it could affect 
the effectiveness of the treatment [182].
Pharmacovigilance data from the European Medicines 
Agency indicate that there are no reports of toxic effects of 
aluminum hydroxide in products for allergen immunotherapy. 
In VIT with a maintenance dose of 200 μg and in VIT with 
2 different venoms, it is preferable to use an aqueous extract 
for at least 1 of the 2 VITs as a precautionary measure [90]. 
A recent paper analyzed the aluminum concentration in urine 
and blood in 2 groups of patients: those never treated with 
aluminum-depot subcutaneous immunotherapy and those 
treated with aluminum depot VIT. No differences were detected 
in urine aluminum concentrations between the 2 groups; the 
same was true of blood using free-gel monovette. However, 
given the small amount of the free-gel detections, data from 
blood remain inconclusive [184].
Currently, there are no guidelines in the literature on the 
management of product deficiency during maintenance, which 
was reported in 2016 owing to the sudden unavailability of some 
extracts. A recent multicenter study prospectively collected data 
on switching VIT and reported that switching VIT from one 
manufacturer to another is a safe option, if necessary, in patients 
who had previously tolerated VIT, even without reducing the 
previous maintenance dose, in a proper medical setting staffed by 
experienced personnel [185,186]. In patients who experienced 
previous severe systemic reactions during VIT, the treatment 
should be restarted with a rush/ultrarush protocol in centers 
experienced in hymenoptera venom allergy and VIT or with a 
conventional protocol in less experienced centers.
Duration
In patients with no specific risk factors, VIT should be 
continued for 5 years [187]. Based on current literature, the 
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Table 8. Risk Factors for Reduced Effectiveness of Venom Immunotherapy (VIT)
Risk Factor  Notes
Age Adults are at higher risk than children, as patients under the age of 16 generally have a more favorable  
 prognosis. VIT is not recommended for cutaneous/mucosal systemic reactions in patients under the age  
 of 16, except in cases of high risk of exposure or impaired quality of life [50,152,235,270].
Bee venom The protection rate for bee venom is lower than for vespid venom [28,73,160,189,191,271]. 
 The reason for this discrepancy is not yet fully understood. Recent studies of molecular allergy have  
 shown that relevant allergens to bee venom may be poorly represented in some extracts used for specific  
 immunotherapy [107,272].
Severity of onset  Patients with severe systemic reactions to hymenoptera sting are less likely to have long-term protection  
 (based on the number and frequency of stings received after suspension of immunotherapy) compared  
 with patients who experience milder reactions [159,188,189,241,271,273].
Systemic reactions  Patients with adverse reactions to VIT are at greater risk of incomplete protection than patients who 
during VIT tolerate VIT [166,191,271].
High tryptase values In some studies, clonal mast cell diseases are correlated with lower clinical efficacy [207,274]. However,  
and clonal mast cell diseases other studies do not support this conclusion and confirm a protection rate of 67%-85%  
 [100,152,255,256,275]. In a recent prospective study, protection was 86% after field sting in patients  
 with clonal mast cell disorders [256]. Overall, VIT should be considered an effective and safe option in  
 these patients.
Angiotensin-converting A single study on 1532 patients reported that this category of drugs could be a risk factor for reduced  
enzyme inhibitors clinical efficacy, as demonstrated by sting challenge [166].
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recommended duration of VIT is 3-5 years in adults and 
children [73,90,187]. One year of VIT did not provide sufficient 
protection in about a quarter of treated patients [188].
After 3 years of VIT, 83% to 100% of patients remain 
protected against subsequent stings for a further 1 to 3 years 
[158,159,188,189-193].
A VIT schedule equal to or longer than 5 years provides 
more prolonged efficacy after the interruption [189,194,195]. 
At present, there are no data on the maintenance of protection 
for periods longer than 15 years, especially in the case of VIT 
with bee venom. Table 9 shows the risk factors for relapse 
after interruption of VIT.
When skin and serological tests yield negative results, VIT 
can be safely interrupted. However, this rarely occurs [73]. 
After 5 years of VIT, there is an average reduction in specific 
IgE of 58%-70% overall compared with baseline and a lower 
reduction in older patients or in patients with very severe 
reactions. This reduction is not correlated with lower clinical 
efficacy [196]. Indeed, the decision to stop VIT cannot be 
based solely on the reduction in specific serum IgE levels, 
since stung and protected patients during VIT have higher IgE 
levels at the end of the 5-year treatment than patients who have 
not been stung, although they are clinically protected [196]. 
It was recently shown that an increase in the IgG/IgE ratio 
correlates with a reduction in the frequency of specific IgE and 
skin reactions in patients who have undergone at least 3 years 
of VIT [197]. However, no validated tests are currently able to 
predict venom tolerance owing to variability in immunological 
parameters during VIT [198].
In clinical practice, the patient is rarely stung during VIT, as 
he/she takes environmental prophylactic measures. It therefore 
becomes difficult to decide whether or not to suspend VIT 
in the absence of proof of field protection. Even though the 
sting challenge test is still the most reliable method and the 
gold standard for monitoring the effectiveness of VIT [90], it 
cannot be performed to demonstrate the effectiveness of VIT 
in some countries for ethical and management reasons [199]. 
A recently developed microsyringe challenge method [200] 
has yet to be validated.
Proper management of patients requires a full knowledge of 
the risk factors that could negatively impact on the protection 
provided by VIT. According to prevalent expert opinion, 
patients with mast cell disease should receive lifelong treatment 
[201,202]. However, this suggestion is not confirmed by 
controlled studies [90]. A recent study in a selected population 
indicated that mastocytosis should be considered in patients who 
experience severe reactions at re-sting after discontinuation of 
VIT. On this basis, patients with mastocytosis and hymenoptera 
venom allergy should receive lifelong VIT [203].
The decision to prolong VIT over 5 years should be 
shared with patients based on specific risk factors and impact 
on quality of life; there is currently no contraindication to 
continuing VIT for more than 5 years.
Patients should always be followed up over time; this 
aspect is not properly addressed in European and American 
guidelines. Based on current knowledge, the present panel of 
experts suggests the following:
– Patients not undergoing VIT but equipped with an 
adrenaline autoinjector because of a previous systemic 
reaction should attend a follow-up visit in case of re-
sting and have their history updated at each re-order of 
adrenaline, including refresher training on device use. In 
the absence of re-sting, it is useful to schedule a follow-
up visit every 2 years, in order to perform skin and/or 
serological allergy tests before further prescription of 
adrenaline.
Table 9. Conditions for High Risk of Relapse After Discontinuation of VIT
Risk Factor  Notes
Adult population compared with pediatric patients [73]
Severe pre-VIT systemic reaction  Based on data from 4 prospective studies recruiting 386 patients with severe reactions 
 at re-sting, 4.1% had mild and 14.5% had severe pretreatment reactions [187].
Allergy to bee venom The risk of systemic reactions after discontinuation of VIT for bee was 16% vs 8% of  
 patients treated with wasp venom [189].The reasons, which are not entirely known,  
 are partly related to the amount of venom delivered with sting and to the amount of  
 venom administered in VIT. It has also been hypothesized that some major bee  
 allergens may be missed or underrepresented in extracts used for VIT [109].
Systemic reaction caused by VIT Patients who developed systemic reactions to VIT had a 38% risk of re-sensitization  
 compared with those who tolerated treatment (7%) [276].
Failure to achieve protection during VIT [192]
Clonal mast cell diseases and elevated  
baseline tryptase levels Please refer to the mastocytosis section.
Repeated stings According to European studies, patients repeatedly stung after discontinuation of VIT 
 have a greater risk of systemic reactions that may become progressively more  
 severe [189]. Professionals who are particularly at risk include beekeepers and  
 gardeners, who need treatment for an indefinite period.
Persistence of high scores in diagnostic tests  
after 5 years of VIT [241]
Abbreviation: VIT, venom immunotherapy.
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– Patients undergoing VIT should undergo monitoring of 
skin reaction and/or determination of specific IgE at 3 and 
5 years or in the case of a systemic reaction to a field sting.
– Patients at risk of multiple stings or with risk factors 
for relapse after interruption of VIT should attend a 
follow-up visit in case of re-sting and have their clinical 
history updated at each re-order of adrenaline, including 
refresher training on device use. 
Adverse Reactions
The literature reveals considerable variation in the 
incidence of adverse effects due to VIT (0%-46%) [204,205]. 
This is likely due to multiple factors, including different 
classification systems for severity, differences in the quality 
of extracts (nonpurified, aqueous, and depot extracts), and 
differences in administration protocols.
A recent systematic review of the literature [90] examined 
11 observational studies: VIT was associated with a 14.2% 
risk of adverse events in patients treated with bee venom 
and a 2.8% risk in those treated with vespid venom. Another 
systematic review [206] reported a mean frequency of 28.9% 
for adverse events with bee venom, of which 50.4% were 
systemic reactions and 10% local extended reactions.
Large-scale studies showed that most reactions to VIT 
occurred in the build-up phase, including systemic reactions 
(up to 20% [1.9% during the build-up phase, 0.5% during 
maintenance from a total of 26 601 injections]), of which 8.4% 
were moderate to severe [204].
LLRs to VIT are frequent, especially in the build-up phase; 
they do not represent a risk factor for subsequent systemic 
reactions, do not require dose reduction, and do not prevent 
the protective dose from being reached. In the case of systemic 
reactions, it is preferable to reduce the dosage in the build-up 
phase (eg, by stepping down 1 or 2 doses) and continue with 
the last well-tolerated dose [90].
The risk factors for systemic reactions during VIT are bee 
venom, high basal tryptase values in patients allergic to wasps, 
mast cell clonal diseases, and rush and ultrarush protocols 
[73,204,207,208].
However, some authors do not consider rush or ultrarush 
induction protocols to be dangerous, since they were able 
to demonstrate a low risk of systemic reactions and a safety 
profile equivalent to or even better than slower protocols 
[163,209-211].
Local adverse reactions are less frequent with depot 
extracts than with aqueous extracts [212,213]. A systematic 
review confirmed that the incidence of systemic reactions 
is significantly higher for bee venom than for vespid venom 
(25.1% vs 5.8%), while no differences were found between 
aqueous and depot extracts in treated patients [214]. However, 
this review did not compare nonpurified aqueous extracts with 
purified aqueous extracts. In fact, the use of purified aqueous 
extracts seems to correlate not only with a lower frequency 
of major local reactions, but also with a lower frequency of 
systemic reactions than nonpurified extracts [215,216].
Results from double-blind, placebo-controlled studies 
show that premedication with antihistamines improves 
tolerance to VIT while maintaining efficacy [217-220]. 
On this basis, recent EAACI guidelines [90] recommend 
antihistamines, which can prevent extensive local reactions 
and mild systemic reactions. The possibility of masking 
warning signs and symptoms of more severe reactions, 
especially if rapid protocols are used, led the Italian expert 
panel to indicate this treatment as optional.
Off-label premedication with omalizumab can be 
successfully implemented in patients who experience systemic 
reactions to VIT and when premedication with antihistamines 
is insufficient [221,222].
VIT and Pregnancy
Studies on the safety of VIT in pregnancy are 
limited [223,224], mainly for ethical reasons. One of 
the potential risks of immunotherapy, in addition to the 
management of possible adverse reactions, could be the 
induction of a TH2-TH1 cytokine shift that acts against the 
overall TH2 profile of pregnancy and has been claimed to 
prevent fetal rejection [225]. In a 1990 study of 26 patients with 
multiple pregnancies undergoing VIT, the authors estimated a 
3%-5% risk of field sting anaphylaxis in women not undergoing 
VIT during pregnancy, while the risk of anaphylactic reaction 
during VIT was 1% in the maintenance phase and 5% in 
the build-up phase. In addition, anaphylaxis has potentially 
severe consequences for the fetus. The risk of maternal-fetal 
complications in pregnant women undergoing VIT was similar 
to that of women not undergoing VIT [224].
In a 2002, Markert et al [226] reported a case of preterm 
delivery due to placental abruption at week 24 in a woman who 
had started the build-up phase of immunotherapy during the 
first weeks of gestation. VIT was continued at the maintenance 
dose of 50 µg. Analysis of the placenta demonstrated a TH1 
pattern with infiltrated cytotoxic T lymphocytes [226]. In 
contrast, a more recent case report of in vitro fertilization 
considered VIT to be safe [227].
In conclusion, as confirmed by recent European 
guidelines [228], immunotherapy should not be started during 
pregnancy. However, given the low risk of adverse effects, 
VIT should not be interrupted during pregnancy if the patient 
is already taking and tolerating VIT [204].
Adherence to VIT
Adherence to specific immunotherapy is key to successful 
management of patients with respiratory allergies [229]. In the 
case of VIT, a recent Italian study showed high percentages of 
adherence at 3 years (95%) and 5 years (84%) of treatment [230]. 
Pediatric Aspects
Although the efficacy of VIT is known in children, there 
are no double blind, placebo-controlled trials in pediatric 
patients [231]. Treatment is recommended in children who 
experience systemic reactions with cardiovascular and/or 
respiratory involvement after hymenoptera stings [73,231].
In children who only experience cutaneous systemic 
reactions, VIT is not routinely performed [90,232,233], since a 
long-term prospective study has shown that children with this 
type of reaction have a 10% risk of systemic reaction [131]. 
However, there may be particular situations of increased risk of 
re-sting (eg, children of beekeepers), possibly associated with 
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concern on the part of parents and children, distance from an 
emergency department, and unavailability of school staff who 
know how to administer antiallergic drugs. These conditions 
also highlight the need for VIT in cases of children affected 
only by urticaria [73].
As far as the risk of systemic reactions with respiratory 
or cardiovascular involvement is concerned, an observational 
study of pediatric patients followed for 15-20 years showed 
that the risk of recurrence of anaphylaxis in untreated children 
was 32%, compared with 1%-3% in those treated with 
VIT [154]. In a recent 6-year follow-up European pediatric 
study, 62% of children allergic to venom and not treated with 
VIT tolerated subsequent stings, whereas 18% had severe 
systemic reactions [234]. The proportion of therapeutic 
failure of VIT is lower in children than in adults (about 2% of 
treatments) [49,189,235].
Induction patterns in children are similar to those used 
in adults [131]. Regarding accelerated protocols, a pediatric 
study [236] of 43 children and adolescents (aged 4 to 18 years, 
with a 1-4 Mueller grade systemic reaction after bee or wasp 
sting) undergoing ultrarush VIT found no systemic reactions. 
A recent study of pediatric and adult patients confirmed the 
tolerability of the rush schedule in children [237]. Another 
study compared the safety of 3-day rush induction protocols 
Table 10. Pediatric Aspects of Hymenoptera Venom Allergy 
Epidemiology Hymenoptera venom allergy is the second cause of severe reactions in children (20.2%), after food allergy [19]. 
 Prevalence: asymptomatic sensitization, 3.7% [42]; large local reactions, between 0.9% [43] and 20.8% [44];  
 systemic reactions, <1% [15,42]. 
 Risk factors for systemic reactions [45,46]: bronchial asthma, atopy (according to some studies) 
 Clinical: the cutaneous and cardiocirculatory systems are the most affected; skin symptoms are the only clinical  
 manifestation in 60% of cases [47]. 
 Prognosis: favorable regarding re-sting in studies with sting challenge [48] and field sting [49,50].
Diagnosis – Diagnosis is no different from that of adults 
 – The degree of skin sensitization does not correlate with the severity of the reaction [131].
Specific  Indications: 
immunotherapy  – Children who develop a systemic reaction with cardiovascular and/or respiratory involvement [73,232]. 
(VIT) – VIT is usually not administered in children with only cutaneous systemic reactions [90,233] owing to the very  
  low risk of developing a more severe systemic reaction. 
 – Children with an increased risk of exposure (eg, children of beekeepers) and/or children or their parents  
  who show anxiety, are living far from emergency departments, or attending school not staffed with personnel  
  trained to administer antiallergic drugs may also undergo VIT in cases of skin reactions only [73].
 Risk of anaphylaxis at re-sting: 
 – Children not undergoing VIT: 32% vs 1%-3% of patients treated with VIT [154]. 
 – Recent European study with 6-year follow-up: 18% of non–VIT-treated patients (while 62% tolerated  
  subsequent stings) [233].
 Efficacy: 
 – The percentage of failure of VIT in children is lower than that of adults (about 2%) [49,189,235]. 
 – The prognosis after discontinuation of VIT is better than that of adults: only 5% of children with a severe  
  pretreatment reaction develop nonsevere systemic reactions at re-sting [149], compared with 16% of  
  adults [241].
 Induction schemes: 
 – As in adults [131]. 
 – Accelerated (rush, ultrarush) and clustered protocols are well tolerated by children [236-240] 
 – As in adults, avoid excessively rapid patterns with bee venom 
 – As in adults, the maintenance dose is 100 µg, to be increased to 200 µg in unprotected patients
 Duration: 
 – The panel of experts suggests at least 5 years of VIT in pediatric patients 
 – Proper follow-up and appropriate educational programs are necessary.
Quality of Life – Allergy to hymenoptera venom in children can have a negative impact on the quality of life of their parents. 
 – There are specific questionnaires on the quality of life of pediatric patients allergic to hymenoptera venom  
  and their parents [269].
Use of adrenaline  Dose: intramuscular adrenaline in the vastus lateralis muscle at 0.01 mg/kg (maximum dosage 0.3 mg)
 Autoinjector: 
 – The fixed dosage involves a risk of administering a higher or lower dose of adrenaline; for children weighing  
  between 15 and 30 kg with severe anaphylactic reaction or concomitant bronchial asthma, it is advisable to  
  use the adult dosage. 
 – It should be prescribed to children with systemic reactions (not just cutaneous reactions), with a high risk of  
  exposure, risk factors for lacking clinical protection, elevated baseline mast cell tryptase levels, or mast cell  
  disorders [28,33,70,71].
193
Management of Venom-Allergic Children and Adults
J Investig Allergol Clin Immunol 2019; Vol. 29(3): 180-205© 2019 Esmon Publicidad
doi: 10.18176/jiaci.0310
with conventional 4-month regimens [238]: no differences 
were found between the protocols in terms of systemic 
reactions (19% and 23.2% with rush and conventional 
protocols, respectively). In a 2016 study [239], the ultrarush 
induction protocol of Birnbaum et al [240] (101 µg cumulative 
in 210 minutes) was compared in adults and children (systemic 
reactions in 7.7% of adults vs 3.7% of children). It is important 
to remember that, as in adults, excessively rapid schedules 
should be avoided when using bee venom [237].
Children have a better prognosis than adults with 
regard to the maintenance of efficacy upon discontinuation. 
Golden et al [154] followed patients for 20 years and found 
that nonsystemic reaction recurred at re-sting in only 5% of 
children with a severe pretreatment reaction, compared with 
16% of adults [241].
Among 40 children who received VIT for a mean 
of 3 years, 50% developed a new anaphylactic reaction after 
a median follow-up of 13 years; of note, 95% had not received 
adequate follow-up after discontinuation of VIT [242].
In view of these data, the panel of experts suggests that VIT 
should last for at least 5 years in pediatric patients. Moreover, 
children should also undergo periodic check-ups, and suitable 
educational programs are necessary.
Table 10 summarizes the pediatric aspects of hymenoptera 
venom allergy.
Management of the Patient With 
Concomitant Diseases
Heart Disease
The presence of cardiovascular disease is a major risk 
factor in hymenoptera venom–allergic patients owing to the 
severity of anaphylaxis after a sting. In fact, increased mast cell 
density has been identified in arterial intima and adventitia in 
ischemic heart disease, aortic valve stenosis, and hypertrophic 
cardiomyopathy [243]. Furthermore, mast cells in ischemic 
myocardium are richer in histamine and tryptase than mast 
cells in healthy myocardium.
Venom components can induce the release of serotonin 
and adrenaline, which increase platelet aggregation, thus 
increasing the likelihood of thrombosis resulting from an 
increase in factor V and the release of a thromboplastin-like 
substance from the vessel wall. These and other substances 
released by mast cells could have a negative inotropic and 
chronotropic effect. During the anaphylactic reaction, de novo 
synthesis of LTC4 and PGD2 at the level of the heart may 
result in vasoconstriction. Similarly, in some patients with 
coronary artery disease, stimulation of H1 receptors may cause 
vasoconstriction of large-caliber coronary arteries, in contrast 
to patients with a healthy myocardium [244]. Activation 
of metalloproteinase also degrades the connective tissue of 
atheromatous plaques, thus increasing the risk of ischemia.
Physiologically, the decrease in blood pressure that occurs 
in the anaphylactic reaction leads to reduced perfusion in the 
sinuses of Valsalva and to coronary hypoperfusion.
Kounis syndrome [245], also known as cardiac anaphylaxis, 
is characterized by signs and symptoms that are similar to 
those of coronary syndrome. This condition may be due to the 
direct action of the venom on the coronary endothelium or to 
degranulation of mast cells due to the allergic reaction, with 
direct release of inflammatory mediators into the coronary 
vascular system (histamine, kinase, tryptase) and synthesis 
of leukotrienes, which act as powerful vasoconstrictors of the 
coronary arteries [246].
In patients allergic to hymenoptera venom, in whom a 
subsequent allergic reaction may be more severe or even 
fatal, VIT is elective, even if the patient has had a myocardial 
infarction or severe ventricular arrhythmia. In these patients, 
VIT was found to be associated with a low incidence of 
systemic reactions and with a certain degree of efficacy [247].
The patient with heart disease is often treated with 
ß-blockers and angiotensin-converting enzyme (ACE) 
inhibitors, which are commonly prescribed for hypertension 
and heart failure. ß-Blockers can reduce the efficacy of 
adrenaline administered to treat systemic reactions to 
hymenoptera venom. However, their use is not contraindicated 
during VIT [228]. Indeed, a recent report indicated that 
β-blockers had no significant clinical effects with respect to 
the need for adrenaline dosing in patients with anaphylaxis 
seen in the emergency department [248].
Suspension of ß-blockers, which is limited to the rush or 
ultrarush induction phase of VIT, should be discussed with 
cardiologists. ACE inhibitors can increase the severity of the 
reaction in patients not treated with VIT, although they do not 
seem to increase the risk of systemic reactions during VIT. 
According to a recent study [166], ACE inhibitors constitute 
a risk for reduced protection of VIT to insect challenge. 
Therefore, their suspension remains at the discretion of the 
clinician based on the risk-benefit ratio [16].
Before starting VIT, cardiovascular disease, its 
pharmacological treatment, and the risk of anaphylaxis with 
consequent administration of adrenaline should be carefully 
evaluated on an individual basis, preferably together with 
the consulting cardiologist (strength of recommendation, D).
Elderly Patients
According to the guidelines of EAACI and the American 
Academy of Allergy, Asthma and Immunology (AAAAI), VIT 
should be taken into consideration in older adults, even if they 
have experienced a nonsevere systemic reaction, provided that 
they have risk factors such as concomitant vascular diseases, 
treatment with ACE inhibitors and/or ß-blockers, severe 
chronic obstructive pulmonary disease, and reduced quality 
of life due to the previous anaphylactic event [73,87].
No increased risk of adverse effects or an increase in 
emergency treatments of elderly patients has been demonstrated 
to date (strength of recommendation, D).
Malignancy
Malignant neoplasms are considered absolute 
contraindications for specific immunotherapy with aeroallergens, 
although not all guidelines agree. This contraindication has been 
established for safety and ethical reasons [249], since the risk of 
an exacerbation of neoplastic disease by allergen immunotherapy 
is only theoretical, although a possible immunological 
interaction between neoplasm, cancer treatments, and allergen 
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immunotherapy cannot be completely excluded. However, in 
patients allergic to hymenoptera venom with a high risk of severe 
reactions to subsequent stings (eg, previous life-threatening 
reaction or clonal mast cell diseases), VIT appears to prevent 
fatal events even in the presence of cancer [228,250] (strength 
of recommendation, D).
Autoimmune Diseases and Immunodeficiency
Some guidelines consider multiorgan autoimmune 
diseases in remission to be relative contraindications for 
immunotherapy. If autoimmune diseases are clinically 
active, the contraindication is absolute [228] (strength of 
recommendation, D).
VIT is not contraindicated in patients with organ-specific 
autoimmune diseases (eg, diabetes mellitus, Hashimoto 
thyroiditis, Crohn disease, ulcerative colitis, rheumatoid 
arthritis), provided the disease is stabilized before starting 
treatment [251] (strength of recommendation, D).
Immunodeficiency has a different impact and a different 
pathophysiological mechanism. According to some guidelines, 
concomitant treatment with immunosuppressive drugs means 
that allergen immunotherapy is contraindicated, since they 
could have a negative impact on the effectiveness of VIT. 
HIV infection, in particular, is a relative contraindication 
to VIT that can be assessed on an individual basis (strength 
of recommendation, D). AIDS with a confirmed category C 
disease (1993 Revised Classification, Centers for Disease 
Control) is an absolute contraindication to VIT [228] (strength 
of recommendation, NR).
Mastocytosis
Anaphylaxis is the most severe clinical manifestation of 
systemic mastocytosis, and hymenoptera stings are reported to 
be the most frequent cause (19%-53% of cases) [252].
The preferential association between mastocytosis and 
allergy to hymenoptera venom is well known and widely 
studied [100]. The prevalence of hymenoptera venom 
allergy in the European adult population is between 0.3% 
and 8.9% and rises to 20%-30% in patients with mast cell 
disorders [3,252,152]. On the other hand, the prevalence of 
systemic mastocytosis in the general population is 1-1.3 cases 
per 10 000, which increases significantly in patients with 
hymenoptera venom allergy (5%-8%) [25,252].
Patients with systemic mastocytosis without skin 
involvement presenting hymenoptera venom anaphylaxis 
probably represent a specific phenotype characterized by an 
excellent prognosis, male predominance, lower values of serum 
tryptase, and lower proportions of bone marrow mast cells than 
in indolent forms. Moreover, this phenotype does not include 
other symptoms due to mediator release and affects no myeloid 
lineages other than mast cells [253]. In contrast, hymenoptera 
anaphylaxis appears to be absent in patients with aggressive 
forms of systemic mastocytosis, despite the greater mast cell 
burden [254]. In patients with onset of mastocytosis after 
hymenoptera anaphylaxis, progression to aggressive forms 
and associated hematological malignancies are rarely reported.
After initial debate focusing mainly on the safety and 
efficacy profile of VIT in patients with mastocytosis [100], this 
treatment is now considered safe and efficacious [252,255,256], 
inducing protection from severe allergic reactions to 
subsequent stings.
Given reports of life-threatening and even fatal reactions 
to hymenoptera stings after discontinuation of treatment, 
long-term VIT (probably lifelong) may be recommended 
[100,203]. Patients not adequately protected by the usual 
maintenance dose of 100 μg should have their dose increased 
to 200 μg [252]. Patients affected by systemic mastocytosis 
with a history of anaphylaxis should always carry 2 adrenaline 
autoinjectors. This recommendation is also valid for patients 
receiving VIT [252].
Professional Aspects
Hymenoptera stings are the most frequent cause of 
occupational anaphylaxis and can be attributed to a specific 
work environment [257].
Since exposure to repeated stings is a key factor for the 
development of allergic reactions, persons working outdoors or 
in environments where hymenoptera live are considered to be 
at high risk. In addition to beekeepers [13], for whom a specific 
risk is recognized, other workers such as foresters, farmers, 
gardeners, truck drivers, masons, and electricians [258,259] 
also experience systemic reactions more frequently, as do 
greenhouse workers, who are exposed to bumblebee stings 
[8,260]. For these categories, hymenoptera venom allergy can 
be considered an occupational disease [259,261] necessitating 
specific primary prevention measures [262]. Hymenoptera 
venom allergy is a recognized cause of work disability that 
can require a worker to change or leave his/her profession in 
order to reduce the risk of exposure [263].
Given its degree of effectiveness, VIT is also recommended 
for moderate systemic reactions to enable the worker at risk 
to continue working [14,190,257,262].
Some European authors recommend verifying the efficacy 
of treatment through sting challenge before the resumption 
of work [262], although this clinical practice is not currently 
permitted in Italy. A maintenance dose of 200 μg may be 
indicated for beekeepers [73]. Persons with occupational 
bumblebee-induced anaphylaxis have a low degree of cross-
reactivity with bee venom and therefore should undergo 
VIT with bumblebee venom [8]. Since workers who are 
frequently exposed to stings have a higher risk of relapse after 
discontinuation of VIT, some experts recommend continuing 
treatment for as long as the patient is at risk owing to his/her 
profession [262].
A recent Italian study conducted on 184 patients with 
anaphylactic reactions to hymenoptera venom showed 
an occupational cause in 17.4% of cases; of these, 71.8% 
continued to work after having received VIT. Re-stung workers 
(31.2%) were effectively protected [261]. The impact of VIT 
on professional activity increases with occupational risk [263].
Quality of Life
A history of previous allergic reactions to hymenoptera has 
a negative influence on the quality of life of affected patients. 
Many live their lives in constant anxiety about being stung and 
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experiencing the same or even more severe and potentially 
fatal reactions [264].
Questionnaires were validated to specifically evaluate 
the quality of life of persons allergic to vespids [151,265], 
including P dominula, in the Mediterranean area [266]. 
Randomized controlled clinical trials evaluating the impact of 
hymenoptera venom allergy on quality of life confirmed that 
immunotherapy is associated with a significant improvement 
in quality of life 1 year after initiation of therapy [151,267].
People undergoing immunotherapy have a better quality 
of life than those who are only prescribed the adrenaline 
autoinjector, even if they experienced a systemic reaction of 
medium severity such as urticaria or angioedema. Moreover, 
sting challenge results in a significant improvement in disease-
specific quality of life in patients allergic to hymenoptera 
venom receiving VIT [265-268].
These findings should be taken into account when 
choosing whether to start immunotherapy in persons who 
experienced a cutaneous systemic reaction, and in some cases, 
immunotherapy should be preferred to the prescription of 
adrenaline autoinjectors alone [81].
In the case of children allergic to hymenoptera venom, 
the disease can have an impact on the quality of life of their 
parents. Through specific questionnaires, it was shown that 
parents of hymenoptera venom–allergic children have a worse 
quality of life: in addition to feeling responsible for the life and 
health of their children, parents fear the severe consequences 
of a sting [269].
Conclusions
The severity of allergic reactions to hymenoptera stings 
varies considerably and can sometimes be fatal. Although 
the epidemiological burden of hymenoptera venom allergy is 
similar to that of food allergy, awareness of this problem is poor 
in the general population and among health care providers and 
political decision-makers. Similarly, the availability of acute 
emergency treatment (adrenaline autoinjector) and long-term 
immunotherapy modifying the natural history of this allergy 
remains poor. This observation is somewhat paradoxical 
considering the numerous scientific innovations in this field 
over the past 5-10 years.
It is therefore mandatory to improve both knowledge and 
management of this condition and to ensure that clinicians are 
aware that VIT is by far the most effective form of allergen-
specific immunotherapy available.
This consensus document should be made accessible to 
health care professionals and to anyone looking for information 
on allergic reactions to hymenoptera venom. It provides 
practical advice supported by scientific evidence on both 
diagnosis and therapy and can be used by specialists in daily 
clinical practice. 
As in many other areas of medicine, studies performed in 
the coming years [90,151] will provide data that will facilitate 
the treatment of allergic patients.
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